Traphaco Holds the CEO Handover Ceremony for the 2021-2026 Executive Term

The ceremony welcomed distinguished guests representing major shareholders, including Mr. Nguyễn Quốc Huy – General Director of SCIC, and Ms. Đặng Thị Thu Hà – Head of Investment Division 2, SCIC. From Traphaco, participants included Mr. Trần Túc Mã – Meritorious Physician, Member of the Board of Directors, and Former CEO for the 2021-2026 term, Ms. Đào Thúy Hà – Member of the Board of Directors and newly appointed CEO, along with the Board of Directors, Supervisory Board, Executive Board, leadership of subsidiary companies, and a large number of Traphaco’s managerial staff and employees.

The CEO Handover Ceremony for the 2021-2026 Executive Term officially takes place

Mr. Kim Dong Hyu delivers the opening remarks on behalf of the Chairman of Traphaco’s Board of Directors

The program opened with remarks by Mr. Kim Dong Hyu, speaking on behalf of the Chairman of the Board of Directors. He expressed profound appreciation for Mr. Trần Túc Mã’s outstanding contributions throughout more than three decades of dedicated service, including 15 years as CEO. He highlighted Mr. Mã’s foundational role in guiding Traphaco through the unprecedented challenges of the COVID-19 pandemic, ensuring the uninterrupted supply of essential medicines amid severe pressure on the healthcare system and supply chains.

He also emphasized several strategic milestones achieved during Mr. Mã’s tenure: the completion and operation of the state-of-the-art Traphaco Hung Yen Pharmaceutical Plant; the pioneering adoption of GACP standards for medicinal herb cultivation; the implementation of the delivery-and-immediate-collection sales model; the company’s decisive digital transformation; and preparations for a new distribution structure aligned with the revised Pharmaceutical Law. He affirmed that these achievements represent only a small part of the enduring values Mr. Mã has helped build for Traphaco. On behalf of the Board of Directors, he congratulated Ms. Đào Thúy Hà on her appointment as CEO and expressed strong confidence in her leadership capability and vision for Traphaco’s next growth phase.

Mr. Nguyễn Quốc Huy – General Director of the State Capital Investment Corporation (SCIC) – delivers his remarks at the ceremony

Representing the major shareholder, Mr. Nguyễn Quốc Huy – General Director of the State Capital Investment Corporation (SCIC) – acknowledged Mr. Mã’s contributions not only as CEO but also as the long-time representative of state capital at Traphaco. He commended the company’s remarkable achievements under Mr. Mã’s leadership, including three First-Class Labor Orders, multiple prestigious domestic and international awards, and consistent, sustainable business performance. He expressed his expectation that Ms. Hà, in her new role, would continue to advance major initiatives such as the EU-GMP manufacturing project and Traphaco’s international product development strategy, ensuring long-term value for shareholders and employees.

Former CEO Trần Túc Mã shares his reflections at the ceremony

In his address, Mr. Trần Túc Mã – Former CEO – reflected on his 33-year journey with Traphaco across three leadership terms marked by transformative milestones. Between 2011 and 2016, Traphaco became the first pharmaceutical company in Vietnam to adopt the delivery-and-immediate-collection sales model and implement the DMS management system, setting new standards of transparency and distribution efficiency. The company also developed GACP-WHO–certified medicinal herb cultivation zones, laying the groundwork for standardized herbal medicine production nationwide.

From 2016 to 2021, Traphaco achieved a major breakthrough with the construction of the Hung Yen Smart Pharmaceutical Plant, completed in only two years. The project was recognized as one of Vietnam’s Top 10 Science and Technology Events of 2017. After just five years of operation, the plant had fully recovered its investment capital and became the company’s strategic technological platform, including preparations for the EU-GMP project.

During the 2021–2025 period, Traphaco navigated the disruptions caused by the COVID-19 pandemic. Through early market forecasting and proactive supply planning, the company ensured stable availability of essential medicines and maintained steady business growth. The company also implemented a comprehensive restructuring of its sales system, expanded digital transformation and AI applications, and established a dedicated logistics subsidiary, laying a solid foundation for the new distribution model aligned with the Pharmaceutical Law.

Mr. Mã stressed that his decision to transition from the CEO role was not driven by external pressure or personal considerations, but by deliberate and forward-looking evaluation of Traphaco’s development needs. With the 2026–2030 period expected to bring major shifts in national digital transformation, regulatory requirements, advanced technological standards, and global competitiveness, he emphasized that Traphaco must be led by a CEO well-equipped to guide this next development cycle. He noted that this moment—when the company is performing strongly, systems are firmly established, and the next generation of leaders has matured—is the most appropriate time for this transition. As a Member of the Board of Directors, he committed to continuing to support the Executive Board and especially the new CEO in strategic orientation. He called on SCIC, major shareholders, and all employees to uphold the spirit of innovation that has shaped Traphaco’s identity for decades.

CEO Đào Thúy Hà delivers her remarks at the ceremony

In her inaugural remarks, Ms. Đào Thúy Hà – newly appointed CEO – expressed heartfelt gratitude to SCIC, major shareholders Mirae Asset and Daewoong Pharmaceutical, Chairman Chung Ji Kwang, and Mr. Trần Túc Mã, whom she described as a mentor and an important guiding influence throughout her career. She shared her pride in nearly 30 years of dedication to Traphaco, witnessing key milestones such as the company becoming Vietnam’s first pharmaceutical enterprise to undergo equitization in 1999, listing on HOSE in 2008, and undergoing several major restructuring and expansion phases. With Vietnam advancing toward greater transparency, nationwide digital transformation, and a national strategy aimed at turning the pharmaceutical industry into a regional hub for high-value medicine production, Ms. Hà affirmed that Traphaco stands before significant opportunities for breakthrough growth.

She pledged to maintain double-digit growth, accelerate the EU-GMP project, solidify Traphaco’s leading position in herbal pharmaceuticals, expand investments in modern pharmaceuticals, intensify digital transformation and AI integration, and cultivate young talent—a critical foundation for long-term sustainable development. She called upon all Traphaco employees to unite, innovate, and dedicate themselves to the shared goal of elevating Traphaco into a leading pharmaceutical corporation with international standing.

The signing ceremony of the CEO’s handover minutes between Mr. Trần Túc Mã and Ms. Đào Thúy Hà

The signing of the handover minutes took place in a solemn and unified atmosphere, symbolizing the cohesion and continuity across generations of Traphaco’s leadership. The ceremony concluded with renewed confidence in a new chapter of growth, where Traphaco continues to build on its long-standing legacy of innovation, leadership, and aspiration for excellence.

Members of the Board of Directors, Supervisory Board, Executive Leadership of Traphaco and its subsidiaries, along with department leaders, pose for a commemorative photo with the Former and the Newly Appointed CEO